A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)
Brief description of study
Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This study is being done to see whether a new medication, called CXA-10, can reduce the amount of protein in the urine and maintain stable kidney function in patients with primary FSGS. CXA-10 is an investigational medication which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary FSGS. The pharmaceutical company sponsoring this study is Complexa, inc.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
FSGS,Primary Focal Segmental Glomerulosclerosis,
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
29 Sep 2022.
Study ID: 831546